非阻塞性斑块特征在症状和无症状冠状动脉疾病中的重要性
Martina C de Knegt1, Jesper J Linde1, Per E Sigvardsen1
1Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Journal of cardiovascular computed tomography
|February 6, 2024
概括
在所有患者群体中,非阻塞性冠状动脉疾病 (CAD) 斑块在体积上明显超过阻塞性斑块. 斑块组成,不包括密集的,随着临床严重程度的增加而恶化.
科学领域:
- 心血管成像 - 心血管成像
- 动脉样硬化研究 动脉样硬化研究
- 量化计算机断层扫描 (QCT) 是一种技术.
背景情况:
- 冠状动脉疾病 (CAD) 斑块负担在阻塞性和非阻塞性疾病之间有所不同.
- 了解斑块组成对于CAD中的风险分层至关重要.
研究的目的:
- 使用QCT量化和比较不同CAD种群中的阻塞性和非阻塞性斑块体积和组织组成.
- 为了研究斑块特征和临床表现之间的关系.
主要方法:
- 定量计算断层扫描 (QCT) 用于分析855名患有CAD的参与者的冠状动脉斑块体积.
- 参与者被分为无症状患者,没有急性冠状动脉综合征 (ACS) 的急性胸痛患者和患有ACS的患者.
- 斑块组成 (密,纤维,纤维脂肪,死核) 在参与者层面进行了评估.
主要成果:
- 在所有人群中,非阻塞性斑块体积始终大于阻塞性斑块体积 (p<0.0001).
- 纤维,纤维脂肪和死核组织的体积随着临床表现的恶化而增加 (ACS>胸痛>无症状).
- 非阻塞性密集体积在两组之间没有显著差异 (p>0.3).
结论:
- 非阻塞性CAD是亚临床和临床CAD中动脉样硬化斑块总体体积的主要驱动因素.
- 斑块组成,特别是纤维,纤维脂肪和死核组成部分,与临床疾病严重程度相关.
- 非阻塞性密集与临床表现的严重程度无关.
相关概念视频
01:17Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
01:38Inflammation
53.4K
Overview
53.4K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
515
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
515